YOU ARE HERE: LAT HomeCollectionsHuman Immuno Deficiency Virus

Human Immuno Deficiency Virus

May 9, 2007 | From Times Wire Reports
Former President Clinton announced agreements with drug companies to lower the price of "second-line" AIDS drugs for people in the developing world and to make a once-a-day AIDS pill available for less than $1 a day. The anti-retroviral drugs are needed by patients who develop resistance to first-line treatment and cost 10 times as much as first-line therapy, Clinton said in New York. Nearly half a million will require these drugs by 2010.
April 25, 2007 | From the Associated Press
The federal government should approve a novel drug that targets the cells of HIV-infected patients and not the virus itself, health advisors recommended Tuesday. The 12 advisors unanimously voted to urge the Food and Drug Administration to approve maraviroc, which Pfizer Inc. hopes to sell under the brand name Celsentri. It would represent the first so-called CCR5 receptor antagonist to be sold.
April 21, 2007 | From Reuters
An experimental Pfizer Inc. AIDS pill was effective at suppressing the HIV virus when added to the best available drug regimens, U.S. drug reviewers said in an analysis released Friday. The Food and Drug Administration staff, however, said they would ask an advisory panel that meets Tuesday for advice "regarding the possible need for special labeling as well as whether additional clinical trials should be performed to address particular safety issues."
April 5, 2007 | Jia-Rui Chong, Times Staff Writer
A new AIDS drug that received accelerated federal approval last summer is significantly better at attacking highly resistant HIV than existing drugs, according to a study of 230 patients published Wednesday. Darunavir, part of the decade-old class of drugs known as protease inhibitors, lowered virus levels to the undetectable range in 45% of patients after 48 weeks. By comparison, 10% of patients on other drug regimens showed similar declines.
March 31, 2007 | From Times Staff and Wire Reports
HIV-positive women who breastfeed exclusively are less than half as likely to transmit the virus to their babies as women who use a mixture of breastfeeding and formula, South African researchers reported Friday in the medical journal Lancet. Exclusive breastfeeding ordinarily protects the integrity of the intestinal mucosa, which thereby presents a more effective barrier to HIV, they said. It also is associated with fewer breast problems that can cause an increased viral load in breast milk.
March 2, 2007 | Francisco Vara-Orta, Times Staff Writer
A majority of Los Angeles County primary care practitioners are failing to advise their Latino patients -- who are at high risk for HIV infection -- to get tested, according to a UCLA study released Thursday. Only 41% of the 85 surveyed primary care providers -- including doctors, nurses and physician assistants -- had regularly offered advice about sexually transmitted diseases during the six-month period covered in the study, which was conducted in 2004 by the UCLA AIDS Institute.
March 1, 2007 | Jia-Rui Chong, Times Staff Writer
Two experimental AIDS drugs designed to fight resistant HIV strains are showing promising preliminary results, researchers said Wednesday. One, called elvitegravir, is part of a new class of drugs known as integrase inhibitors and has shown evidence of being more potent than currently used drugs.
February 26, 2007 | Jia-Rui Chong, Times Staff Writer
A highly drug-resistant form of tuberculosis has killed about 85% of South African HIV patients who have become infected, presenting one of the most worrisome problems in HIV and tuberculosis control, researchers reported Sunday. About 330 cases of so-called extensively drug-resistant, or XDR, tuberculosis have been verified in South Africa over the last year, said Karin Weyer of the South African Medical Research Council in Pretoria.
February 24, 2007 | From Times Wire Reports
Treating genital herpes may slow the progression of HIV, the AIDS virus, in those infected with both viruses, researchers reported Wednesday in the New England Journal of Medicine. The test involving 140 women in the West African country of Burkina Faso found that when herpes was being treated with 500 milligrams of the drug valacyclovir twice daily for three months, the women were less likely to spread the AIDS virus.
January 13, 2007 | From Times Staff and Wire Reports
Pregnant women who are HIV-positive and take the drug nevirapine during labor to prevent infecting their babies should wait until six months after delivery to resume taking the drug to avoid developing resistance, researchers reported this week in the New England Journal of Medicine. The drug is increasingly used in the developing world to prevent HIV transmission to infants, but 42% of women who resume taking it within six months rapidly develop resistance.
Los Angeles Times Articles